24/7 Wall St. on MSN13d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
Morgan Stanley sees ‘limited impact’ to Lilly shares from Novo CagriSema data
Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Devdiscourse47m
Eli Lilly's Global Expansion Plan for Blockbuster Drug Mounjaro
Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...
Fierce Pharma1h
GSK, Novartis, Lilly among Big Pharmas celebrating International Women’s Day 2025
Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...
Novo Nordisk (0QIU) Gets a Hold from Bernstein
In a report released today, Courtney Breen from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...
Medical Marketing & Media2d
Novo, Lilly and Novartis lead pharma’s stellar ad performance at Oscars
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...